For research use only. Not for therapeutic Use.
Simufilam（Cat No.:I044447）is a novel small-molecule drug candidate developed to treat Alzheimer’s disease by targeting altered filamin A (FLNA), a scaffolding protein that becomes misfolded in the disease. By restoring FLNA’s normal structure, Simufilam disrupts its pathological interactions with receptors involved in inflammation and neurodegeneration, such as the α7 nicotinic acetylcholine receptor and toll-like receptors. This correction leads to improved synaptic function, reduced neuroinflammation, and stabilization of cognitive performance. Simufilam has shown encouraging results in preclinical and early clinical trials, supporting its potential as a disease-modifying therapy for neurodegenerative disorders.
| CAS Number | 1224591-33-6 |
| Synonyms | 4-benzyl-8-methyl-1,4,8-triazaspiro[4.5]decan-3-one |
| Molecular Formula | C15H21N3O |
| Purity | ≥95% |
| IUPAC Name | 4-benzyl-8-methyl-1,4,8-triazaspiro[4.5]decan-3-one |
| InChI | InChI=1S/C15H21N3O/c1-17-9-7-15(8-10-17)16-11-14(19)18(15)12-13-5-3-2-4-6-13/h2-6,16H,7-12H2,1H3 |
| InChIKey | BSQPTZYKCAULBH-UHFFFAOYSA-N |
| SMILES | CN1CCC2(CC1)NCC(=O)N2CC3=CC=CC=C3 |
| Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |
